Molecular Partners Ag Stock Analysis

Molecular Stock Analysis Notes

The company has price-to-book ratio of 0.9. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners recorded a loss per share of 1.79. The entity had not issued any dividends in recent years. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Molecular Partners operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 163 people. To find out more about Molecular Partners AG contact Patrick Amstutz at 41 44 755 77 00 or learn more at https://www.molecularpartners.com.

Molecular Partners Investment Alerts

Molecular Partners Upcoming and Recent Events

Molecular Largest EPS Surprises

View All Earnings Estimates

Molecular Partners Environmental, Social, and Governance (ESG) Scores

Molecular Partners Thematic Classifications

Molecular Stock Institutional Investors

Note, although Molecular Partners' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Molecular Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 143.88 M.

Molecular Profitablity

Management Efficiency

Molecular Partners has return on total asset (ROA) of (0.2144) % which means that it has lost $0.2144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3398) %, meaning that it created substantial loss on money invested by shareholders. Molecular Partners' management efficiency ratios could be used to measure how well Molecular Partners manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of March 2025, Return On Tangible Assets is likely to grow to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.44. At this time, Molecular Partners' Total Assets are very stable compared to the past year. As of the 26th of March 2025, Non Current Assets Total is likely to grow to about 5 M, while Other Current Assets are likely to drop about 2.1 M.

Technical Drivers

As of the 26th of March, Molecular Partners secures the Standard Deviation of 4.04, mean deviation of 2.69, and Risk Adjusted Performance of (0.07). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Partners, as well as the relationship between them.

Molecular Partners Price Movement Analysis

Molecular Partners Outstanding Bonds

Molecular Partners Predictive Daily Indicators

Molecular Partners Corporate Filings

Molecular Partners Forecast Models

Molecular Partners' time-series forecasting models are one of many Molecular Partners' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Molecular Partners' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Molecular Partners prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Molecular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Molecular Partners. By using and applying Molecular Stock analysis, traders can create a robust methodology for identifying Molecular entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Molecular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Molecular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Molecular Partners AG stock analysis indicators help investors evaluate how Molecular Partners stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Molecular Partners shares will generate the highest return on investment. By understating and applying Molecular Partners stock analysis, traders can identify Molecular Partners position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.